William Shergy

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Roy Fleischmann, Eduardo Mysler, Stephen Hall et al. · The Lancet · 2017 · 479 citations

Rheumatoid Disorder, Rheumatology, Tofacitinib Monotherapy +8

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve‐month results of a phase iib, double‐blind, randomized, placebo‐controlled trial

Joel M. Kremer, Maxime Dougados, Paul Emery et al. · Arthritis & Rheumatism · 2005 · 445 citations · Full text

Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose‐finding, double‐blind, placebo‐controlled clinical trial evaluating CTLA‐4Ig and LEA29Y eighty‐five days after the first infusion

Larry W. Moreland, Rieke Alten, Filip Van den Bosch et al. · Arthritis & Rheumatism · 2002 · 379 citations

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

René Westhovens, M. Robles, Antônio Carlos Ximenes et al. · Annals of the Rheumatic Diseases · 2009 · 347 citations · Full text

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

Robin K. Dore, Stanley Cohen, Nancy E. Lane et al. · Annals of the Rheumatic Diseases · 2009 · 192 citations · Full text